Design, synthesis, and evaluation of a mitoxantrone probe (MXP) for biological studies
Savanna Wallin1, Sarbjit Singh1, Gloria E O Borgstahl1
1The Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, United States.
Abstract:
Mitoxantrone (MX) is a robust chemotherapeutic with well-characterized applications in treating certain leukemias and advanced breast and prostate cancers. The canonical mechanism of action associated with MX is its ability to intercalate DNA and inhibit topoisomerase II, giving it the designation of a topoisomerase II poison. Years after FDA approval, investigations have unveiled novel protein-binding partners, such as methyl-CpG-binding domain protein (MBD2), PIM1 serine/threonine kinase, RAD52, and others that may contribute to the therapeutic profile of MX. Moreover, recent proteomic studies have revealed MX's ability to modulate protein expression, illuminating the complex cellular interactions of MX. Although mechanistically relevant, the differential expression across the proteome does not address the direct interaction with potential binding partners. Identification and characterization of these MX-binding cellular partners will provide the molecular basis for the alternate mechanisms that influence MX's cytotoxicity. Here, we describe the design and synthesis of a MX-biotin probe (MXP) and negative control (MXP-NC) that can be used to define MX's cellular targets and expand our understanding of the proteome-wide profile for MX. In proof of concept studies, we used MXP to successfully isolate a recently identified protein-binding partner of MX, RAD52, in a cell lysate pulldown with streptavidin beads and western blotting.
Insights
Researchers developed a novel mitoxantrone-biotin probe (MXP) to identify new protein targets of this chemotherapy drug. This probe successfully isolated RAD52, a known mitoxantrone-binding protein, in cell lysates, aiding the study of its complex cellular interactions.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Mitoxantrone (MX) is a chemotherapy drug primarily known for DNA intercalation and topoisomerase II inhibition.
- Recent studies suggest MX interacts with additional proteins beyond its canonical targets, potentially influencing its therapeutic effects.
- Understanding these interactions is crucial for elucidating MX's full mechanism of action and cytotoxicity.
Purpose of the Study:
- To design and synthesize a mitoxantrone-biotin probe (MXP) and a negative control (MXP-NC).
- To utilize MXP for identifying and characterizing direct cellular binding partners of MX.
- To expand the understanding of the proteome-wide interactions of mitoxantrone.
Main Methods:
- Design and synthesis of a mitoxantrone-biotin probe (MXP) and a negative control (MXP-NC).
- Application of MXP in cell lysate pulldown assays using streptavidin beads.
- Detection of bound proteins via western blotting.
Main Results:
- Successful synthesis of MXP and MXP-NC.
- Proof-of-concept study demonstrated MXP's ability to isolate known MX-binding partners.
- RAD52, a recently identified MX-binding protein, was successfully isolated using MXP from cell lysates.
Conclusions:
- The developed MXP is an effective tool for identifying MX's direct cellular targets.
- This approach facilitates the characterization of MX's binding partners and expands the understanding of its proteome-wide interactions.
- The findings provide a molecular basis for alternative mechanisms influencing mitoxantrone's cytotoxicity.
